Becton Dickinson vs Resmed (BDX vs RMD)
Side by side from their SEC filings: revenue, margins, growth, returns and valuation, plus short interest, insider activity and institutional ownership.
Becton Dickinson is the larger company by revenue ($21.8B vs $5.1B) and market value ($41.9B vs $28.8B). Resmed has grown revenue faster over the last 4 fiscal years (+61.0% cumulative vs +14.2%). Resmed runs the higher operating margin (32.7% vs 11.8%). Resmed trades at the lower trailing P/E (19.1x vs 26.5x).
About Becton Dickinson
Becton Dickinson & Co (BD) is a global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products. Its products serve healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. BD operates through three main segments: BD Medical, which offers medical technologies and devices; BD Life Sciences, which provides diagnostic and research tools; and BD Interventional, which supplies vascular, urology, oncology, and surgical specialty products.
About Resmed
ResMed Inc develops and sells products and software for sleep and breathing health, including treatments for obstructive sleep apnea (OSA). The company serves healthcare providers, sleep clinics, and patients by offering devices and cloud-based business management software for residential care. ResMed focuses on innovation to compete in a market with evolving technology and alternative therapies.
Head to head (BDX FY2025 vs RMD FY2025)
| Metric | BDXFY2025 | RMDFY2025 |
|---|---|---|
| Revenue | $21.84B | $5.15B |
| Revenue growth (YoY) | 8.2% | 9.8% |
| Gross margin | 45.4% | 59.4% |
| Operating margin | 11.8% | 32.7% |
| Net margin | 7.7% | 27.2% |
| Net income | $1.68B | $1.40B |
| Diluted EPS | $5.82 | $9.51 |
| FCF margin | 12.2% | 32.3% |
| ROE | 6.6% | 23.5% |
| Debt / equity | 0.7× | 0.1× |
| Market cap | $41.87B | $28.79B |
| P/E (TTM) | 26.5× | 19.1× |
Fundamentals are from each company’s SEC filings (BDX FY2025, RMD FY2025). P/E and market cap are derived from recent market prices and update daily.
Five-year trend (as reported)
| Revenue | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| BDX | $19.13B | $18.87B | $19.37B | $20.18B | $21.84B |
| RMD | $3.20B | $3.58B | $4.22B | $4.69B | $5.15B |
Peer standing
Where each company ranks among the 88 medical device companies, on the same scale. Each figure is ranked only against peers that report it. Percentiles describe position in the distribution, not a rating.
| Metric | BDX | RMD |
|---|---|---|
| Gross margin | 45.4%22nd percentile of 77 | 59.4%42nd percentile of 77 |
| Operating margin | 11.8%76th percentile of 80 | 32.7%Highest of 80 |
| Net margin | 7.7%73rd percentile of 81 | 27.2%98th percentile of 81 |
| FCF margin | 12.2%71st percentile of 74 | 32.3%97th percentile of 74 |
| Revenue growth (YoY) | +8.2%35th percentile of 87 | +9.8%38th percentile of 87 |
| ROE | 6.6%67th percentile of 79 | 23.5%91st percentile of 79 |
| P/E (TTM) | 26.5×39th percentile of 32 | 19.1×26th percentile of 32 |
| Debt / equity | 0.69×66th percentile of 54 | 0.11×17th percentile of 54 |
| Short interest (days to cover) | 2.90d40th percentile of 88 | 8.49d98th percentile of 88 |
Short interest
| FINRA settlement data | BDX | RMD |
|---|---|---|
| Shares sold short | 11.2M | 15.1M |
| Change vs prior settlement | +54.4% | +16.9% |
| Days to cover | 2.90 | 8.49 |
| As of settlement | 2026-06-30 | 2026-06-30 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data; republishing or redistributing it is not permitted. Not presented as a percentage of float. No FINRA endorsement of this product is implied.
Insider activity (last 90 days)
| Form 4 open-market activity | BDX | RMD |
|---|---|---|
| Buys | 0 | 0 |
| Sells | 6 ($765,120) | 3 ($3.1M) |
Open-market purchases and sales reported on SEC Form 4 (grants, exercises and tax withholding excluded). For context, about 16% of covered companies saw any open-market insider buy in a 90-day window.
Held by the same investors
6 tracked 13F managers hold both Becton Dickinson and Resmed as of their latest quarterly filings: AQR Capital Management, Bridgewater Associates, Citadel Advisors, Gotham Asset Management, Millennium Management, Two Sigma Investments. See which superinvestors hold your own portfolio with the smart money checker.
Go deeper
BDX vs BSXBDX vs DXCMBDX vs MDLNBDX vs MMMBDX vs SYKBDX vs WSTAll medical device stocks →All comparisons →
Track BDX and RMD
Get an alert when either company files something material, see which superinvestors own them, and ask their filings a question with cited answers.
Start monitoring freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filings before relying on them. Comparisons are descriptive (higher or lower on a reported figure), not a rating or a recommendation. Informational only. Not investment advice.